Biologics Contract Development Market Size, Share, Opportunities, And Trends By Source (Mammalian, Microbial, Others), By Service (Cell Line Development, Process Development, Others), By Indication (Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Others), And By Geography - Forecasts From 2023 To 2028

The biologics contract development market is expected to grow at a CAGR of 16.6% from US$17.712 billion in 2021 to US$51.912 billion in 2028.

The Drugs that target the human immune system specifically are known as biologics. Vaccines, somatic cells, recombinant gene treatments, blood components, and allergic biologic goods are only a few examples of the biologics available in the market. Proteins, tissue, and nucleic acids from living beings make up biologics. These products are isolated using biotechnological techniques from sources including bacteria, animals, and humans. Since this product is extremely susceptible to contamination, pharmaceutical firms have a significant need for biologics contract development.

Biologics contract development market growth drivers

The increase in the number of drug development procedures, an increase in the rate of drug approval by the Food and Drug Administration, an increase in the use of targeted drug therapies, growth in the demand for personalized medicine, and an increase in the incidence of chronic diseases are major factors fueling the biologics contract development market.

In addition, the biologics contract development industry is being driven by factors such as the rising adoption of advanced technologies for biologic development, the favourable environment for clinical trials in developing nations, the surge in the number of collaborations, contracts, and mergers with local players to develop advanced biologic products, and the rising demand for the treatment of rare diseases.

Increasing incidences of various disorders in people

The prevalence of diseases including neurological disorders, gynaecological disorders, cancer, ophthalmic disorders, and cardiovascular disorders is constantly rising. For instance, according to the WHO, cancer was one of the leading causes of death worldwide and responsible for over 10 million fatalities in 2020. Healthcare CDMOs can be crucial to the treatment of patients in these situations. For the treatment of illnesses, several biopharmaceutical companies are creating cutting-edge treatments or ground-breaking solutions.

Upstream process development to show significant market growth potential

The creation of upstream processes mostly entails choosing the appropriate cell line, culture medium, bioreactor systems, and operational parameters. The majority of companies that manufacture biologics offer upstream process development services, which are highly tailored to the demands of the client's company, the limitations of applicable regulations, and the project schedule which is fueling the biologics contract development market. To thoroughly investigate the manufacturing of vaccines, medication metabolism, and cytotoxicity, the creation of artificial tissues, gene function research, the production of antibodies, and the synthesis of biological chemicals, cell lines are reportedly employed by NCBI.

Technological advancements in the biologics contract development market

CDMOs are significantly expanding the biologics contract development market share due to cutting-edge technology and specialized knowledge. In a highly competitive sector, biopharmaceutical CDMOs have the best chance of success. They are prepared to adopt cutting-edge technologies and make the required time and financial commitments to develop competitive advantages. The top CDMOs will boost capacity fast while remaining adaptable and nimble.

In response to the growing incidence of infectious illnesses and the rising need for innovative treatments, pharma, and biotech firms that need larger financial expenditures for cutting-edge technologies are collaborating with CDMOs, which is fostering the biologics contract development market share.

The North American biologics contract development market is anticipated to grow significantly.

The biologics contract development market in North America is anticipated to grow significantly. This is related to rising R&D expenditures, the local presence of multinational corporations, and those corporations' efforts to get new patents. Many biologics contract development industry expansion by various organizations is responsible for North America’s rising clinical trial activity. For instance, according to ClinicalTrial.Gov almost 32% of all trials completed worldwide as of July 2022, were undertaken in the United States alone. Furthermore, various studies conducted in the United States are fueling the biologics contract development market share.

Asia Pacific is also predicted to show significant growth

The biologics contract development market is anticipated to witness the greatest CAGR in Asia Pacific during the projected period. Biotechnology businesses are becoming more interested in investing in the Asia Pacific area as a result of several regulatory organization adjustments to modify clinical trial evaluation criteria following global needs. Asia Pacific nations provide potential with a vast patient pool and cutting-edge medical knowledge. The expense of doing a clinical study is quite cheap in the region when compared to Western nations.

Various companies focus on product innovation

Biologics contract development is a fast-growing industry. The competition is boosted by the advanced technology being inculcated. For the manufacture of biopharmaceuticals, CDOs are moving towards Single-Use Bioreactors (SBUs), lower batch sizes, and reduced-volume bioreactor tank sizes. Furthermore, various mergers and acquisitions in developing countries by key players in the region are fueling the market. For instance, Lonza and biotechnology business Touchlight joined in September 2022 to expand their product line with other sources of DNA for producing mRNA. Through Lonza's products, Touchlight hopes to increase the number of consumers using its innovative doggy bone DNA (dbDNA) technology.

Market Key Developments

• In March 2023, for the construction of a new factory in South Korea, Samsung Biologics declared an investment of USD 1.5 billion.
• In March 2023, Lonza and Simris Alg AB of Sweden collaborated to create and produce antibody-drug conjugates.
• In February 2023, Lonza increased its footprint in the United States by opening a new lab devoted to creating medications that are still in the early phases of clinical testing.

Segmentation:

• By Source
  • Mammalian
  • Microbial
  • Others
• By Service
  • Cell Line Development
  • Process development
  • Others
• By Indication
  • Oncology
  • Immunological Disorders
  • Cardiovascular Disorders
  • Hematological Disorders
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others